The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth.

GLP-1 Momentum Versus Diversified Stability

Lilly’s quarter centered on its diabetes and obesity franchise. Revenue hit $17.6 billion, driven by Mounjaro and Zepbound demand that management described as supply-constrained rather than demand-constrained. Net income of $5.6 billion jumped 480% year over year, as operating margin expanded to 48.3%. Gross margin reached 82.9%, reflecting the pricing power and manufacturing efficiency of blockbuster biologics.

Johnson & Johnson’s $24.0 billion in revenue came from a broader base. Medical device sales benefited from elective procedure volume recovery. Pharmaceutical revenue grew on newer immunology and oncology drugs, though legacy products faced biosimilar pressure. The 69.6% gross margin and 30.2% operating margin reflect a more complex cost structure spanning manufacturing, distribution, and regulatory compliance across multiple product categories. Net income of $5.2 billion rose 91% year over year, driven partly by one-time gains visible in its Q1 2025 blowout of $4.54 EPS against $2.26 expected.

One Franchise Versus Portfolio Breadth

Lilly’s strategy concentrates risk and reward in a single therapeutic area. GLP-1 drugs now define the company’s valuation and growth trajectory. Management invested $4.1 billion in R&D during the quarter, much directed toward expanding manufacturing capacity and developing next-generation obesity treatments. The forward P/E of 33.78 reflects confidence that demand will sustain through patent cliffs and competitive entries.

Johnson & Johnson spreads exposure across devices, pharmaceuticals, and international markets. The company spent $3.7 billion on R&D allocated across oncology, immunology, cardiovascular devices, and surgical robotics. This diversification limits upside but cushions against single-product risk. The forward P/E of 18.05 and 2.45% dividend yield position J&J as a defensive holding rather than a growth bet.

Oral Competition and Manufacturing Scale

The next inflection point for Lilly involves oral GLP-1 competition. Novo Nordisk’s oral Wegovy approval in December 2025 triggered sustained Reddit discussion, with one thread generating 168 upvotes and comments noting the shift from injections to pills could reshape patient preferences. Lilly must prove its injectable franchise can hold share as oral alternatives scale.

Johnson & Johnson faces different tests. Device segment growth depends on hospital capital spending, which remains uneven. Pharmaceutical revenue needs newer drugs to offset biosimilar erosion on older biologics.

Why I Lean Toward Lilly Despite the Premium

I would choose Lilly for exposure to a transformational drug category that still has room to run. The 480% earnings growth and 48.3% operating margin suggest the GLP-1 franchise is hitting scale efficiently. The P/E of 53.22 looks steep, but the PEG ratio of 1.01 indicates growth justifies the multiple. Oral competition is real, but Lilly’s manufacturing lead and pipeline depth give it time to adapt.

Johnson & Johnson fits a different investor. If you prioritize income and stability over growth, the 2.45% yield and diversified revenue base make sense. The stock gained 44.84% over the past year, but long-term returns lag dramatically. Lilly delivered 587.71% over five years versus J&J’s 51.34%.